Major global investors continued to accumulate PolTREG shares in 2023, adding another 129,000 shares, and bringing the total to 1.27 million. Investment funds including well-known investors like TFI Allianz Polska – part of the Allianz Group – and Norges Bank Investment Management, collectively hold over 25% of PolTREG’s shares. The trust of these global investors underscores the significant commercial potential of the cell therapies against autoimmune diseases PolTREG S.A. is developing.
2024-02-07
Global institutional investors and investment funds hold over 25% of PolTREG’s shares.
See other news
2024-09-16
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
2024-09-09
PolTREG Treg cell therapy for patients with type-1 diabetes shows long-term clinical remission and insulin independence
2024-07-24
The European Medicines Agency has granted PolTREG preliminary approval to launch a new Phase 2 clinical trial in presymptomatic Type-1 Diabetes.
2024-06-25
PolTREG will get access to new groups of type-1 diabetes patients with its Treg cellulartherapies after signing a cooperation deal with the University Clinical Center in Gdansk
2024-06-24
Positive results of a long-term safety and efficacy study of PTG-007 in early-onset type-1 diabetes
2024-06-13
PolTREG received approval to operate a genetic engineering facility from Poland’s ministry of Climate and Environment
2024-05-14
PolTREG received a patent in the US protecting the manufacturing of T-regulatory cells to treat Type-1 Diabetes, and ways the therapy is administered